FAQ| NEWLY DIAGNOSED | SYMPTOMS | CHAT ROOM & message BOARDS| in memory of Janis

JANIS AND FRIENDS HEPATITIS C WEB SITE

latest news

HOME

HCV NEWS

INTERNET CONFERENCES

HCV TRIALS

WHATS NEW AT J&F

HCV ARCHIVES

page updates

VX950-TELAPREVIR

other HCV Information

HISTORY OF HCV

GLOSSARY/ABBREVIATIONS

LIVER FUNCTIONS

QUESTIONS ABOUT HCV

EXTRAHEPATIC CONDITIONS

SYMPTOMS

TRANSMISSION

SEXUAL TRANSMISSION

HCV BLOOD TESTS/LABS

LABS ON TREATMENT

BIOPSY RESULTS

ALTERNATIVE TO BIOPSY

STILL NEED A BIOPSY ?

ON BIOPSY WHAT DOES THE STAGE MEAN AND WHAT DOES THE GRADE ME ?

STAGES/LIVER DISEASE

FIBROSIS

CIRRHOSIS

TRANSPLANTS

LIVER CANCER

GENOTYPES

VIRAL LOAD

PEGASYS/ PEGINTRON

INFERGEN

HELP/SIDE EFFECTS

DRUG INTERACTIONS

NUTRITION & HCV

TREATMENT STORIES

FIRST SHOT

INTERVIEWS

FIND A DOCTOR

FINANCIAL AID/MED ETC

SUPPORT GROUPS/TRANSPLANTS

HCV SUPPORT GROUPS

PICTURES Of OUR FRIENDS

INFORMATIONAL LINKS

This Web Site is committed to the memory of Janis Morrow.

Human liver

Articles on all genotypes & Latest Treatments

2005

INDEX

2006 Research

Back to Main Genotype Page

(Back to : Archives With All 2004 - 2001 Research )

2005 Research

Page Two

24 vs 48 weeks Pegasys/RBV in HCV Genotype 2/3 Coinfection:
does this study answer the question

Sep 01 2005

Treatment of Genotype 4 HCV

Aug 10 2005

European Union's CHMP Adopts Positive Opinion for Shorter Course of PEGINTRON(R) and REBETOL(R) Combination Therapy for Certain Hepatitis C Patients with Genotype 1 and Low Viral Load

Aug 4 2005

Peginterferon-α-2a (40KD) and Ribavirin for 16 or 24 Weeks in Patients With Genotype 2 or 3 Chronic Hepatitis C

Aug 3 2005

Short Term Therapy for Genotype 2a

June 04 2005

Enrollment Completed for Phase IIb Trial of Valopicitabine plus Pegasys Combination Therapy for HCV Genotype 1 Patients Non-responsive to Peginterferon/Ribavirin

June 01 2005

Etanercept Treatment to Slow Fibrosis Progression Shows No Histological or Biochemical Improvement in Chronic HCV Genotype 1 Nonresponders to Peginterferon/Ribavirin

June 01 2005

Predictors of Treatment Failure in Patients with Hepatitis C Genotypes 2 or 3

June 01 2005

Efficacy of 24 Weeks of Treatment with Peginterferon Alfa-2b (PegIntron) Plus Ribavirin in Patients with HCV Genotype 1 and Low Viral Load

May 30 2005

Page One

Peginterferon Alfa-2a/ribavirin Treatment in Patients with Chronic HCV Genotype 1: Efficacy Is Improved in Patients with Early Stages of Fibrosis

May 18 2005

Peginterferon Alfa-2b (PegIntron) Therapy for 8 Weeks in Acute Hepatitis C Genotypes 1 and 4: A Pilot Study

May 18 2005

Efficacy of Daily Consensus Interferon (Infergen) and Ribavirin Compared to Peg-Interferon Alfa2b (PegIntron) and Ribavirin in Treatment-Naive Patients with HCV Genotype 2 or 3

May 15 2005

No Correlation Found Between Steatosis and Liver Fibrosis in HCV Genotype 1 Infection

May 05 2005

HCV genotype 5 has a similar response to peginterferon plus ribavirin as genotype 1

April 19 2005

In Genotype 1 Patients with Low Viral Load Who Become HCV RNA Negative at Week 4, Treatment with Peginterferon Alfa-2b (PegIntron) for 24 Weeks Has Similar High Efficacy with Superior Safety Compared to 48-week Therapy

DOES THE CLINICAL OUTCOME OF HEPATITIS C INFECTION VARY WITH THE INFECTING HEPATITIS C VIRUS TYPE?

April 19 2005

Nine of 10 Chronic Hepatitis C Patients Achieve a Cure 24 Weeks Post-treatment with High Dose Ribavirin Plus Standard Dose Peginterferon Alfa-2a (Pegasys)

Response to Treatment in Patients with HCV Genotype 5

Budget Impact Analysis of 2 Different Methods of Evaluating Early Viral Response to Peginterferon Alfa-2b (Peg-Intron) Plus Ribavirin Therapy in Genotype 1 Patients

Comparison of 2 Doses of Peginterferon Alfa-2b Plus Weight-based Ribavirin for Treatment-naïve Patients with Genotype 1 HCV

Research Archives

(Back to : Archives With All 2004 - 2001 Research )